Benzinga | Jun 1, 2021 07:09AM EDT

Bruker Highlights Launch Of timsTOF trueSCP

* Unique timsTOF trueSCP revolutionizes quantitative single cell biology research with unbiased, deep single-cell 4D-Proteomics(tm) to complement scRNA-seq; breakthrough paper by Mann et al. identifies and quantifies >1,400 proteins in single cells

* Next-generation timsTOF Pro 2 with unprecedented depth and throughput for unbiased 4D-Proteomics; supports liquid biopsy multiomic biomarker research, integrating genomics with proteomics and epiproteomics; identifies ~6,000 proteins/60,000 peptides on 200 ng, and ~4,000 proteins/30,000 peptides on just 20 ng of HeLa digests with 30 minute gradients

* Progress in unbiased plasma proteomics, cancer proteogenomics, 4D-Epiproteomics(tm) for PTM analysis, targeted proteomics for LDT development, and immunopeptidomics for neoantigen discovery in immunooncology by our timsTOF collaboration partners

* New PaSER real-time 4D-Proteomics software enables visualization of MOMA CCS-enabled separation of co-eluting or isobaric peptides, advances phosphoproteomics cancer research; GPU de novo peptide sequencing enhances immunopeptidomics; novel TIMScore(tm) increases confidence of peptide IDs and protein numbers at same FDRs

At Bruker's virtual 4D-Proteomics(tm) eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation (NASDAQ:BRKR) today announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Bruker's collaborators are making major progress in unbiased single cell proteomics, phosphoproteomics and plasma proteomics, leveraging the speed, sensitivity and dynamic range of large-scale CCS-enabled 4D-Proteomics and 4D-Epiproteomics.